CF AMR Syndicate
Cross-sector initiative advancing cystic fibrosis antimicrobial research through collaboration and knowledge exchange.
The CF AMR Syndicate is a collaborative initiative formed in 2019 by Medicines Discovery Catapult and Cystic Fibrosis Trust, later joined by LifeArc, to address antimicrobial resistance in cystic fibrosis. This syndicate operates by bringing together experts from industry, academia, and clinical settings, along with individuals affected by cystic fibrosis, to foster innovation in antimicrobial development. The organization serves a diverse range of stakeholders, including researchers, healthcare professionals, and patients, by facilitating collaboration and knowledge exchange in cystic fibrosis infection research. The CF AMR Syndicate's business model revolves around creating a network that accelerates the development of effective antimicrobial treatments, thereby generating value through partnerships and funding programs. The syndicate's efforts are recognized in the industry, as evidenced by its shortlisting for a Bionow award. Keywords: cystic fibrosis, antimicrobial resistance, collaboration, research, development, healthcare, network, innovation, partnership, treatment.
